Previous 10 | Next 10 |
4 Top Biotech Stocks To Know About This Week With COVID-19 resurging, health care stocks appear to be on investors‘ radars once again. For the most part, this part of the stock market today is home to many companies fighting the pandemic now. This would be the case whethe...
Shares of BeyondSpring (NASDAQ: BYSI) soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung cancer treatment. By the close of trading, BeyondSpring's stock price was up 176% after rising as much as 211% earlie...
Wednesday was generally a down day in the stock market, with major indexes showing losses of as much as 1%. However, the Nasdaq Composite (NASDAQINDEX: ^IXIC) held up quite well, just barely falling below the unchanged mark as of noon EDT. Most people think of tech stocks when t...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of BeyondSpring (NASDAQ: BYSI ) stock are taking off on Wednesday following an important update regarding the firm’s lung cancer treatment. Source: CI Photos / Shutterstock.com The pharmaceutical c...
BeyondSpring (BYSI +158.2%) has more than doubled in value to reach a two-year high in morning hours after the company said its DUBLIN-3 trial met the primary endpoint for Plinabulin and docetaxel (DP) combination in non-small cell lung cancer. Seeing “a dramatic shift in the thes...
Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...
BeyondSpring (NASDAQ:BYSI) soars 332.5% premarket after announcing positive topline data of DUBLIN-3 trial in plinabulin in combination with docetaxel (DP) to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (D) (n=559). The combination met the pri...
Study met primary endpoint showing statistically significant improvement in overall survival (OS) for the combination vs. docetaxel. Study met key secondary endpoints showing statistically significant improvement for the combination against docetaxel alone in ORR, PFS, and 24-...
BYSI has a November PDUFA for plinabulin in chemo-induced neutropenia. There are certain ways in which plinabulin and Spectrum's rolontis complement each other. Below is an overview of plinabulin and a comparison. For further details see: BeyondSpring's Plinabulin: Upcom...
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Direct...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtua...